X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ASTRAZENECA PHARMA ALEMBIC PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 16.9 91.8 18.4% View Chart
P/BV x 3.7 20.2 18.2% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 ALEMBIC PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ASTRAZENECA PHARMA
Mar-18
ALEMBIC PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6641,278 52.0%   
Low Rs412883 46.7%   
Sales per share (Unadj.) Rs208.7228.4 91.4%  
Earnings per share (Unadj.) Rs31.010.4 299.1%  
Cash flow per share (Unadj.) Rs37.116.3 228.2%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.298.8 146.0%  
Shares outstanding (eoy) m188.5225.00 754.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.7 54.5%   
Avg P/E ratio x17.4104.2 16.7%  
P/CF ratio (eoy) x14.566.4 21.8%  
Price / Book Value ratio x3.710.9 34.1%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,46127,008 375.7%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m7,4671,535 486.3%   
Avg. sales/employee Rs ThNM4,210.9-  
Avg. wages/employee Rs ThNM1,132.2-  
Avg. net profit/employee Rs ThNM191.1-  
INCOME DATA
Net Sales Rs m39,3475,710 689.1%  
Other income Rs m94123 76.6%   
Total revenues Rs m39,4415,833 676.2%   
Gross profit Rs m8,736463 1,887.2%  
Depreciation Rs m1,152147 781.8%   
Interest Rs m1840-   
Profit before tax Rs m7,493438 1,710.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568179 876.2%   
Profit after tax Rs m5,844259 2,255.4%  
Gross profit margin %22.28.1 273.9%  
Effective tax rate %20.940.8 51.2%   
Net profit margin %14.94.5 327.3%  
BALANCE SHEET DATA
Current assets Rs m19,5773,209 610.0%   
Current liabilities Rs m14,8962,070 719.8%   
Net working cap to sales %11.920.0 59.6%  
Current ratio x1.31.6 84.8%  
Inventory Days Days9072 124.1%  
Debtors Days Days4535 129.9%  
Net fixed assets Rs m27,097790 3,428.7%   
Share capital Rs m37750 754.0%   
"Free" reserves Rs m26,8112,419 1,108.2%   
Net worth Rs m27,1882,469 1,101.0%   
Long term debt Rs m4,9930-   
Total assets Rs m47,7784,605 1,037.4%  
Interest coverage x41.7NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.81.2 66.4%   
Return on assets %12.65.6 224.3%  
Return on equity %21.510.5 204.8%  
Return on capital %23.617.7 133.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,453300 6,494.0%   
Fx outflow Rs m6,0652,015 301.0%   
Net fx Rs m13,388-1,715 -780.5%   
CASH FLOW
From Operations Rs m8,12088 9,237.3%  
From Investments Rs m-7,556-94 8,072.6%  
From Financial Activity Rs m590NA-  
Net Cashflow Rs m1,153-6 -20,233.3%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 0.3 966.7%  
FIIs % 9.1 15.7 58.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 9.1 152.7%  
Shareholders   49,328 12,856 383.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SANOFI INDIA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  WYETH LTD  TORRENT PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Capital Goods and Realty Stocks Lag(09:30 am)

Asian share markets are mixed today. The Shanghai Composite is lower by 0.3% while the Hang Seng is even. The Nikkei 225 is trading down by 0.7%.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 16, 2019 12:03 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - NATCO PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS